Fundz

Fundz Deep Dive

Everything you need to win Ron Philip — in one platform.

Who to reach, what to say, and why now on Ron Philip — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Ron Philip — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Orbital Therapeutics Appoints Ron Philip As Chief Executive Officer (CEO)

PRIVATESep 03, 2024•almost 2 years ago

Position

Chief Executive Officer

Company

Orbital Therapeutics

Ron Philip
research

Description

Orbital Therapeutics announced the appointment of Ron Philip as chief executive officer (CEO) and a member of its board of directors. Mr. Philip brings to Orbital more than 30 years of biopharma leadership experience

Company Information

Company

Orbital Therapeutics

Location

100 Binney Street

About

Orbital Therapeutics is a biotechnology company founded in 2021 that focuses on developing next-generation RNA-based medicines. The company aims to reprogram the immune system to treat various diseases, including autoimmune disorders, cancer, and infectious diseases through vaccines. Orbital utilizes a comprehensive RNA platform that features circular and linear RNA technologies, targeted lipid nanoparticle delivery systems, AI-guided RNA design, and automation to create precise and durable therapies tailored to specific diseases. The leadership team, including CEO Giuseppe Ciaramell, PhD, and Chief Scientific Officer Giles Besin, PhD, brings extensive experience in RNA therapeutics development. Orbital's lead program, OTX-201, is an in vivo CAR-T therapy designed for B cell depletion, offering a less invasive treatment option for autoimmune diseases. The company is also developing a diverse portfolio of RNA medicines, including next-generation RNA vaccines and RNA immunomodulators. Orbital Therapeutics is committed to advancing RNA medicines that provide safer and more accessible alternatives to current treatments, with a vision to expand their impact globally.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Orbital Therapeutics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.